OCX 191

Drug Profile

OCX 191

Alternative Names: 3-AP; NSC 663249; NSC#663249; NTO-1151; OCX-0191; Triapine

Latest Information Update: 23 Jun 2017

Price : $50

At a glance

  • Originator Yale University
  • Developer Nanotherapeutics; National Cancer Institute (USA); Trethera; Vion Pharmaceuticals
  • Class Antineoplastics; Pyridines; Small molecules; Thiosemicarbazones
  • Mechanism of Action Ribonuclease inhibitors; Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cervical cancer; Gynaecological cancer; Solid tumours
  • Preclinical Leukaemia
  • No development reported Breast cancer; Cholangiocarcinoma; Gallbladder cancer; Haematological malignancies; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer
  • Discontinued Cancer; Cancer metastases; Hepatitis B; Herpes simplex virus infections; HIV infections

Most Recent Events

  • 05 Jan 2017 Preclinical trials in Leukaemia (Combination therapy) in USA (unspecified route)
  • 05 Jan 2017 Trethera plans a phase I trial in Leukaemia (Combination therapy)
  • 05 Jan 2017 OCX 191 licensed to Trethera Corporation worldwide for the treatment of haematological malignancies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top